ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

The Selection Process for Total Artificial Heart

F. Arabia, L. Czer, M. Kittleson, E. Passano, F. Liou, J. Yabuno, H. Henry, D. Chang, F. Esmailian, J. Kobashigawa, J. Moriguchi.

Cedars-Sinai Heart Institute, Los Angeles, CA.

Meeting: 2015 American Transplant Congress

Abstract number: 70

Keywords: Heart failure, High-risk

Session Information

Date: Sunday, May 3, 2015

Session Name: Concurrent Session: "The Pit and the Pendulum": VADs, Dual Organs and Other Matters of the Heart

Session Time: 2:15pm-3:45pm

 Presentation Time: 2:27pm-2:39pm

Location: Room 119-B

Related Abstracts
  • Assessment of Hospital Readmissions After Mechanical Circulatory Support
  • Is There a Protective Value for Low Level Donor Specific Antibodies to Prevent Cardiac Allograft Vasculopathy After Heart Transplant?

Purpose: Heart failure patients with severe biventricular failure who are candidates for heart transplant are considered for Total Artificial Heart (TAH) support. These patients may be in cardiogenic shock (Intermacs 1) and it is unclear as to whether these patients benefit from this newer technology. In the current literature, there is contention as to whether cardiogenic shock or Intermacs 1 patients should have any intervention performed due to high risk of mortality. We sought to evaluate our patients who have undergone TAH placement and outcomes based on their severity of illness/Intermacs level.

Methods: Between 2010 and 2014, we assessed 33 patients who underwent TAH placement. Patients were divided according to their Intermacs level at the time of TAH implantation. This included Intermacs 1 (n=13), Intermacs 2 (n=11) , and Intermacs ≥3 (n=9). Outcomes included 6 month device success (defined as survival and/or bridged to transplant), 6 month actuarial freedom from stroke, gastrointestinal bleed, infection, and renal failure (defined as need for dialysis).

Results: There was a significant decrease in survival in the Intermacs 1 group compared to the Intermacs 2 and ≥3 groups (log-rank p=0.013, see table). There is no significant difference in complications among the 3 groups.

Endpoints Intermacs 1 (n=13) Intermacs 2 (n=11) Intermacs 3-5 (n=9) Log-Rank P-Value
6-Month Actuarial Device Success 46.2% 100.0% 77.8% 0.013
6-Month Actuarial Freedom from Stroke 71.3% 90.9%   0.206
6-Month Actuarial Freedom from GI Bleed 72.0% 60.0% 60.0% 0.812
6-Month Actuarial Freedom from Infection 38.4% 63.6% 50.8% 0.475
6-Month Actuarial Freedom from Renal Failure 100.0% 100.0% 100.0% >0.999

Conclusion: Patients with severe biventricular heart failure who are Intermacs 1 have significantly lower device success questioning the efficacy of this intervention for these patients. Determining a subset of Intermacs 1 patients who may have a higher chance of survival is currently underway.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Arabia F, Czer L, Kittleson M, Passano E, Liou F, Yabuno J, Henry H, Chang D, Esmailian F, Kobashigawa J, Moriguchi J. The Selection Process for Total Artificial Heart [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/the-selection-process-for-total-artificial-heart/. Accessed April 19, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.